Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sinovac rabies vaccine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sinovac rabies vaccine - Batch 1 | EXPERIMENTAL | Subjects will be randomly assigned to receive 5 doses of Sinovac rabies vaccine (Batch 1) on Day 0,3,7,14,28 |
| Sinovac rabies vaccine - Batch 2 | EXPERIMENTAL | Subjects will be randomly assigned to receive 5 doses of Sinovac rabies vaccine (Batch 2) on Day 0,3,7,14,28 |
| Sinovac rabies vaccine - Batch 3 | EXPERIMENTAL | Subjects will be randomly assigned to receive 5 doses of Sinovac rabies vaccine (Batch 3) on Day 0,3,7,14,28 |
| Sinovac rabies vaccine - 5 doses | EXPERIMENTAL | Subjects will be randomly assigned to receive 5 doses of Sinovac rabies vaccine on Day 0,3,7,14,28 |
| Sinovac rabies vaccine - 4-1 doses | EXPERIMENTAL | Subjects will be randomly assigned to receive 4 doses of Sinovac rabies vaccine on Day 0,3,7,14 |
| Sinovac rabies vaccine - 4-2 doses | EXPERIMENTAL | Subjects will be randomly assigned to receive 4 doses of Sinovac rabies vaccine on Day 0,3,7,28 |
| Marketed rabies vaccine - 5 doses | ACTIVE_COMPARATOR | Subjects will be randomly assigned to receive 5 doses of a marketed rabies vaccine in China on Day 0,3,7,14,28 |
| Name | Type | Description |
|---|---|---|
| Sinovac rabies vaccine | BIOLOGICAL | Three batchs of Rabies Vaccine (Serum-free Vero Cell), Freeze-dried using five doses of PEP schedules |
| Marketed rabies vaccine | BIOLOGICAL | A markted Rabies Vaccine using 5 doses of PEP schedules |
Inclusion Criteria: 1. Participants are able to understand and voluntarily sign the Informed Consent Form; 2. Able to provide legal identity documents; 3. Age 18 to 45 years; 4. Stable health status (defined as stable underlying disease status within 3 months prior to enrollment, i.e., no change in...
Sinovac rabies vaccine is an investigational vaccine being studied for rabies prevention in healthy volunteers. It is currently in Phase 3 clinical development. The vaccine is being evaluated for immunogenicity and safety, meaning how well it triggers an immune response and its safety profile in humans.
Sinovac rabies vaccine is developed by Sinovac Biotech, Ltd, a biopharmaceutical company listed on the NASDAQ under the ticker symbol SVA. The company is conducting clinical trials for this vaccine in China.
Sinovac rabies vaccine is in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities. Two Phase 3 trials have been conducted or planned, with one completed and one not yet recruiting.
Sinovac rabies vaccine has two clinical trials. NCT07357545 is a completed Phase 3 study with 2,040 participants evaluating immunogenicity and safety. NCT07416110 is a Phase 3b trial not yet recruiting, with 912 participants, assessing lot-to-lot consistency. Both are conducted in China.
Sinovac rabies vaccine is classified as a monoclonal antibody modality. However, it is being studied as a vaccine for rabies prevention. The trials focus on its immunogenicity and safety in healthy volunteers, with active-controlled, randomized, double-blind designs.